How Big Food Is Navigating the GLP-1 Era

The food industry faces a significant financial threat as the widespread adoption of GLP-1 weight-loss drugs alters consumer eating habits and taste perceptions. With projections suggesting a $30 to $55 billion loss for the sector by 2030, major manufacturers like Conagra are retooling product development to cater to a new, health-conscious demographic. Companies are leveraging data-driven AI personas and specialized test kitchens to create high-protein, fiber-rich offerings that appeal to users who report diminished cravings and altered sensory experiences with traditional snacks. While these firms experiment with "GLP-1 friendly" labeling and reformulated recipes, they must simultaneously maintain their core portfolio of high-fat and high-sugar products to satisfy the broader consumer base. This shift represents a fundamental change in the industry’s playbook, moving away from purely indulgent snacks toward functional foods that align with the physiological needs of a changing population.